• Citer

Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.

par Paridaens, R. ;Roy, J A;Nooij, Marianne;Klijn, J;Houston, S;Beex, Louk;Vinholes, J;Tomiak, E;Van Vreckem, Ann;Langenaeken, C;van Glabbeke, Martine;Piccart-Gebhart, Martine
Référence Anti-cancer drugs, 9, 1, page (29-35)
Publication Publié, 1998-01

Article révisé par les pairs

• Détails
• Contenu

Titre:	Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Auteur:	Paridaens, R.; Roy, J A; Nooij, Marianne; Klijn, J; Houston, S; Beex, Louk; Vinholes, J; Tomiak, E; Van Vreckem, Ann; Langenaeken, C; van Glabbeke, Martine; Piccart-Gebhart, Martine
Informations sur la publication:	Anti-cancer drugs, 9, 1, page (29-35)
Statut de publication:	Publié, 1998-01
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Antineoplastic Agents -- adverse effects
	Antineoplastic Agents -- therapeutic use
	Aromatase Inhibitors
	Breast Neoplasms -- drug therapy
	Enzyme Inhibitors -- adverse effects
	Enzyme Inhibitors -- therapeutic use
	Estrogen Antagonists -- therapeutic use
	Female
	Hot Flashes -- chemically induced
	Humans
	Middle Aged
	Nausea -- chemically induced
	Tamoxifen -- therapeutic use
	Triazoles -- adverse effects
	Triazoles -- therapeutic use
Note générale:	Clinical Trial
	Clinical Trial, Phase II
	Comparative Study
	Journal Article
	Multicenter Study
Langue:	Anglais
Identificateurs:	urn:issn:0959-4973
	info:pmid/9491789